22nd Century Group Inc. develops and commercializes reduced-nicotine tobacco products built on proprietary plant biotechnology. Its VLN® combustible cigarette products use low-nicotine tobacco and are described in company materials as FDA-authorized reduced nicotine cigarettes in the United States. Company updates commonly address VLN retail distribution, state authorizations, PMTA-related product expansion, licensing strategy, tobacco-variety research and engagement with FDA and public-health stakeholders.
News also covers operating results for the tobacco business, including branded VLN products, contract manufacturing volumes, filtered cigars and other distributed tobacco products. Recent company reporting frames results around commercial expansion, cost management, higher-margin branded products and the completed exit from the hemp/cannabis business.
22nd Century Group (Nasdaq: XXII) reported first quarter 2026 results and business updates on May 7, 2026. The company reported net revenues of $4.1 million, a net loss of $3.3 million, adjusted EBITDA loss of $2.6 million, and $9.5 million in cash at quarter end.
Operational highlights include VLN® placement in over 2,000 stores across 20 states, a target to reach 5,000 retail outlets by end-2026, multiple PMTA submissions across combustible categories, completed 100mm product prototyping, and zero long-term debt.
22nd Century Group (Nasdaq: XXII) will report first quarter 2026 results on May 7, 2026. A press release will be issued at 6:00 AM ET, followed by a live webcast at 8:00 AM ET with CEO Larry Firestone and CFO Dan Otto.
The webcast and archived replay are available on the company’s Events page. The company highlights its FDA‑authorized VLN® cigarette, made with proprietary tobacco that contains 95% less nicotine than traditional cigarettes.
22nd Century Group (NASDAQ: XXII) outlined its 2026 priorities focused on scaling its FDA‑authorized VLN® reduced‑nicotine cigarette, expanding retail distribution, and increasing marketing to drive consumer awareness and adoption. The company highlights VLN®'s science, its proprietary non‑GMO tobacco with 95% less nicotine, and early retail traction as the base for growth.
Management cites ~28 million U.S. smokers (over 1 billion worldwide), estimates a >20 million U.S. addressable market of smokers wanting to quit, and plans to increase outlet density and marketing in 2026 while emphasizing regulatory compliance.
22nd Century Group (Nasdaq: XXII) signed a testing services agreement with North Carolina State University to validate reduced‑nicotine tobacco varieties focused on higher yields, improved leaf quality, consistent low‑nicotine content, scalable production, and grower sustainability. The work will include field evaluations, yield calculations, quality assessments and nicotine quantification, building on the company’s proprietary low‑nicotine genetics and FDA‑authorized VLN® combustible cigarette platform.
22nd Century Group (Nasdaq: XXII) is advancing a 100mm VLN® reduced nicotine cigarette and preparing a second PMTA after completing prototyping and initial analytical evaluations.
The company, holder of the only FDA-authorized combustible reduced nicotine cigarette (authorized Dec 2021), plans a broad PMTA portfolio and licensing strategy to target approximately half of the ~$82 billion U.S. cigarette market.
22nd Century Group (Nasdaq: XXII) reported Q4 2025 net revenues of $3.5M and year 2025 revenues of $17.6M, with continuing operations net loss of $2.8M in Q4 and $13.1M for the year.
The company exited 2025 debt-free with $7.1M cash, recovered a $9.5M insurance settlement, eliminated >$8.0M legacy debt, and expanded VLN® retail/state authorizations across multiple partner brands.
22nd Century Group (Nasdaq: XXII) will report fourth quarter and full year 2025 results on March 26, 2026, issuing a press release at 6:00 AM ET and hosting a live webcast at 8:00 AM ET.
Chairman and CEO Larry Firestone and CFO Dan Otto will review results, discuss recent progress and outline 2026 plans. The live and archived webcast will be available on the company's Events page at https://ir.xxiicentury.com/events.
22nd Century Group (Nasdaq: XXII) reported early commercial traction for its FDA-authorized VLN® low nicotine combustible cigarettes. In Q4 2025 the company distributed ~8,800 cartons across ~1,700 new retail outlets, and plans to exceed 5,000 retail points in 2026.
The release cites FDA regulatory developments (Jan 2025 proposed 0.7 mg/g nicotine cap) and reiterates VLN® authorization in Dec 2021 as supporting the company’s market opportunity and distribution expansion.
22nd Century Group (Nasdaq: XXII) preliminarily reported fourth-quarter and full-year 2025 results. Key figures: 2025 revenue $17.6M (down from $24.4M in 2024), 2025 net loss $13.1M, cash $7.1M at year-end and zero long-term debt. Inventory rose to $4.3M.
The company expects audited results on or before March 31, 2026, and will host a conference call. Results are preliminary and subject to year-end audit adjustments.
22nd Century Group (Nasdaq: XXII) issued a 2025 year-in-review letter from CEO Lawrence Firestone highlighting the company’s exit from a multi-year restructuring, relaunch of its VLN® reduced-nicotine cigarette platform, and strengthened balance sheet.
Key facts: VLN® contains ~95% less nicotine, is the only FDA-authorized MRTP combustible cigarette, VLN® relaunched in 2025 and is now in ~2,000 retail locations across 20+ states, and the company eliminated debt and improved liquidity while targeting EBITDA breakeven as higher-margin VLN® sales scale.